Biohaven Pharmaceutical Holding Company Ltd. re-affirmed sales guidance for the full year 2022. For the year, the company expected net product sales of $825 million to $900 million.
Biohaven Pharmaceutical Holding Company Ltd.
Equities
BHVN
VGG111961055
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.56 USD | +0.36% |
|
-0.80% | -77.89% |
May. 31 | Biohaven Insider Bought Shares Worth $996,240, According to a Recent SEC Filing | MT |
May. 15 | Biohaven Insider Bought Shares Worth $512,877, According to a Recent SEC Filing | MT |
1st Jan change | Capi. | |
---|---|---|
-77.89% | 541M | |
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
+12.62% | 26.36B | |
-12.11% | 26.22B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- BHVN Stock
- News Biohaven Pharmaceutical Holding Company Ltd.
- Biohaven Pharmaceutical Holding Company Ltd. Re-Affirms Sales Guidance for the Full Year 2022